3T Biosciences is identifying novel targets for the treatment of solid tumors and other immune-mediated diseases. Current treatment options for solid tumors often have limited or negligible efficacy.  3T is understanding how the immune system recognises, targets and destroys cancer cells to develop novel immunotherapies. To develop immunotherapies, 3T is using their proprietary, novel technology called 3T-TRACE (T cell receptor antigen and cross-reactivity engine) to identify novel targets and therapeutically active T cell receptors (TCRs) and TCR mimetics (TCRm). 3T-TRACE employs machine learning and high-diversity target libraries to create highly specific, safe and more effective cancer treatments. 

<p>3T Biosciences is identifying novel targets for the treatment of solid tumors and other immune-mediated diseases. Current treatment options for solid tumors often have limited or negligible efficacy.  3T is understanding how the immune system recognises, targets and destroys cancer cells to develop novel immunotherapies. To develop immunotherapies, 3T is using their proprietary, novel technology called 3T-TRACE (T cell receptor antigen and cross-reactivity engine) to identify novel targets and therapeutically active T cell receptors (TCRs) and TCR mimetics (TCRm). 3T-TRACE employs machine learning and high-diversity target libraries to create highly specific, safe and more effective cancer treatments. </p>


3T Biosciences

 VISTA Inhibitor Clinical Trials Market Size FDA Approval Patent Report 2025 

Next-generation cancer therapies based on T cell receptors

We're hiring: https://lnkd.in/g_ECZWJj

#proteinsciences #scientistII #seniorscientist

3T platform screens billion-scale TCR targets in oncology - drugdiscoverytrends.com

 Northstrive partners with Yuva Biosciences on obesity and cardiometabolic diseases 

Boehringer Ingelheim acquires T3 Pharma for $509m - Pharmaceutical Technology

Why the immunotherapy startup 3T Biosciences is working with Boehringer Ingelheim - drugdiscoverytrends.com

Intracellular targets as source for cleaner targets for the treatment of solid tumors

 TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update 

Isolation of a Structural Mechanism for Uncoupling T Cell Receptor Signaling from Peptide-MHC Binding

 Boehringer strikes deals with Ribo, 3T Biosciences with combined $2.5B value 

Our 3T-TRACE platform - short for T-Cell Receptor Antigen and Cross-Reactivity Engine - is central to our mission of identifying highly specific and immunogenic targets in solid tumors. By leveraging machine learning and diverse target libraries, we aim to create safer and more effective treatments for cancer patients. 

Discover how we are reshaping the landscape of cancer therapy with 3T-TRACE: https://lnkd.in/g-Y9FQbD

#CancerResearch #3TBiosciences #Immunotherapy #OncologyInnovation #TargetedTherapies


Boehringer Ingelheim, 3T Biosciences Expand Immunotherapy Alliance - Contract Pharma

 Northstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health 


              Emory University announces recipients of the first Max Cooper Prize in Immunology | Emory University | Atlanta GA
            

 Boehringer, 3T Biosciences to develop cancer immunotherapies 

Boehringer Ingelheim and 3T Biosciences enter into a second partnership to develop next-generation cancer immunotherapies - PR Newswire

 Appointments and advancements for March 4, 2025 

I am delighted to congratulate Marvin and welcome Barbara. With these appointments we are well positioned to advance our pipeline of T-cell receptor based therapeutics toward the clinic!

 3T Biosciences Builds Transatlantic Pan-Cancer Research Pipeline to Target Most Difficult-to-Treat Cancers 

 Boehringer double dips at 3T, inking second T-cell anticancer deal to swell potential payday to $538.5M 

Facile method for screening clinical T cell receptors for off-target peptide-HLA reactivity

3T Biosciences Strengthens Leadership Team with Promotion of Marvin Gee, Ph.D., to Chief Research Officer and Appointment of Barbara Sennino, Ph.D., as Senior Vice President and Head of Early Development - PR Newswire

3T Biosciences Debuts with $40 Million Series A Financing - PR Newswire

 Northstrive Biosciences Signs Partnership with Yuva Biosciences to Develop AI-Powered Therapies for Obesity and Cardiometabolic Diseases 

Novel T cell receptor-based solid tumor therapies - Nature

Thiel, Parker said to fund secretive T-cell biotech startup - Fierce Biotech

3T Biosciences Builds Transatlantic Pan-Cancer Research Pipeline to Target Most Difficult-to-Treat Cancers - PR Newswire

We’re pleased to announce Jonathan MacQuitty to 3T’s Board of Directors, effective immediately. Jonathan is a highly respected business leader and venture partner, bringing with him a wealth of expertise in life science and healthcare. He is a Partner for Life Sciences at Lightspeed Venture Partners. Learn more about our newest board member: https://lnkd.in/gfeS_cPj

#BioPharma
#Biotechnology
#LifeSciences


              Scientist II/Senior Scientist – Protein Sciences
            

Boehringer double dips at 3T, inking second T-cell anticancer deal to swell potential payday to $538.5M - Fierce Biotech

At 3T Biosciences, we are dedicated to advancing therapies for solid tumors. Our CEO, Stefan J. Scherer M.D., Ph.D., emphasizes, “3T’s TRACE technology, short for T-Cell Receptor Antigen and Cross-Reactivity Engine, enables us to address one of the biggest challenges in cancer treatment – to identify novel targets and to develop next-generation therapies for solid tumors and other immune-mediated diseases with curative potential.” 

Follow us on LinkedIn as we strive to make a difference in oncology.


Identification of Antigenic Targets

During this year’s American Association for Cancer Research, the organization celebrated significant advancements in our understanding and treatment of cancer in the past year. In December, our Scientific Board member, Christina Curtis, was honored with the AACR’s Outstanding Investigator Award in Breast Cancer Research. Additionally, she received the Susan G Komen Brinker Award for Scientific Distinction in Basic Science, making her the first recipient of both awards in the same year. We are truly thankful to have Christina’s exceptional talent as we strive to develop innovative therapies for solid tumors. 

#Oncology

3T Biosciences 27-Slide Pitch Deck to Raise $40M Series a - Business Insider

Westlake backs 3T to use Stanford tech to land one-two punch on TCR challenges - Fierce Biotech


                Gene signatures derived from transcriptomic-causal networks stratify colorectal cancer patients for effective targeted therapy - Communications Medicine
              

Marvin Gee promoted in 3T leadership appointments - The Pharma Letter

Boehringer Ingelheim, 3T Biosciences enter into second partnership for cancer immunotherapies - Medical Dialogues

Boehringer strikes deals with Ribo, 3T Biosciences with combined $2.5B value - BioWorld MedTech

CFO Anthony Doyle resigns at Biocryst - biocentury.com

 Inhibrx Reports First Quarter 2025 Financial Results 

At 3T, our commitment to patients drives every aspect of our work. 

We harness the power of machine learning to gain insights into how patients' immune systems recognize, target, and eliminate cancer cells. By analyzing samples from patients who have responded to immuno-oncology therapies, we aim to deepen our understanding of the immune system's response to cancer and identify novel T-cell receptor targets that are both prevalent and immunogenic. Our goal? To develop next-generation therapies that are not only safer and more effective but also hold the potential for curative outcomes in challenging cancers.

Stay tuned to learn more about our approaches to precision oncology and how we’re changing the landscape of cancer treatment. Together, we can make a difference!  

#PrecisionOncology #3TBiosciences #Immunotherapy

 Boehringer offers 3T Biosciences $268M to plug its data into biotech's TCR cancer platform 

 Multicistronic chimeric protein expression systems 

Boehringer offers $268M to plug data into 3T's cancer ...

 3T Biosciences Launches $40M at Solid Tumors with TCR Tech 

 TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management 

 Combinatorial cancer immunotherapy 

3T Biosciences Launches $40M at Solid Tumors with TCR Tech - BioSpace

3T Biosciences Expands Leadership Team With Bryan Irving, Ph.D., as Chief Scientific Officer to Progress Tumor-specific Therapies to Clinic - PR Newswire

 citybiz+ Catalio Capital Joins $93 Million Series B for Character Biosciences 

 Boehringer and 3T Biosciences enter second partnership 

We are #hiring a Scientist I/II in therapeutic discovery with a background in protein engineering. At 3T, we believe in working hard and moving quickly to uncover novel targets that can help us create transformative T-cell receptor therapies for a wide range of cancer patients. If you’re passionate about advancing science and making a real difference in patients' lives, we would love to see your application!

https://lnkd.in/gctXJCtu
 
#ScientistJobs #PharmaJobs #BiotechCareers #DrugDiscovery

Cartography Biosciences unearths cancer immunotherapy targets - Labiotech.eu


              Christopher Garcia is the 2024 Passano Award winner
            

Drug Discovery & Development recently highlighted 3T Biosciences' innovative approach to drug discovery, explaining how our platform uses yeast-display technology to directly test billions of protein fragments against tumor-derived immune cells, enabling us to identify novel shared T-cell receptor (TCR) targets and allowing for early safety risk detection.

Click the link to read the full article: https://lnkd.in/gYJUqxBS

#DrugDiscovery #Oncology #Immunotherapy #TCellReceptor

Backed by $40M, a biotech startup targets cancer with help from the immune system - BioPharma Dive

By leveraging machine learning and diverse target libraries, at 3T Biosciences, we aim to create safer and more effective treatments for solid tumor cancer patients. 

Our CEO, Stefan J. Scherer M.D., Ph.D., emphasizes, “The combination of our TCR-mimetic discovery platform with our 3T-TRACE platform, short for T-Cell Receptor Antigen and Cross-Reactivity Engine, uniquely positions us to rapidly generate therapeutics targeting pHLA targets that are devoid of off-target cross-reactivity targeting. It is the ultimate one-two punch to enhance the discovery pipeline from novel target discovery to best-in-class pHLA targeting therapeutics.”

Connect with us to explore potential partnerships in advancing cancer treatment. https://lnkd.in/gCg3mhez

#JPM2025 #JPM25 #BioPharma #Biotech

Silicon Valley Billionaires are Quietly Backing This Stealth Immunotherapy Startup - BioSpace

By leveraging the power of the immune system to recognize, target, and destroy cancer cells, our technology is advancing the development of next-generation therapies that have the potential to be safer, more effective, and even curative for difficult-to-treat cancers.

Follow us on LinkedIn as we continue to advance our promising science.

#CancerResearch #Immunotherapy #PrecisionOncology #Oncology #Biopharma

Peter Thiel and Sean Parker are financing a secretive cancer-fighting start-up, source says - CNBC

 RESEND - Northstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health 

As the year draws to a close, we at 3T Biosciences would like to extend our warmest wishes for a joyful holiday season. We are grateful for the support of our partners, collaborators, and community as we work towards advancing therapies for solid tumors. 

#Biotech #Biopharma #Oncology

 Character Biosciences: $93 Million (Series B) Secured For Advancing Precision Medicine For Progressive Eye Diseases 

 Character’s AMD vision attracts $93 million Series B 

 Marina T Alamanou, PhD on LinkedIn: #science #health #drugdevelopment #drugdiscovery #ai #biotech… 

We are excited to share groundbreaking research from our Chief Development Officer Estelle Marrer-Berger, Ph.D., that was recently published in Nature Communications.

The study, based on research conducted while at Roche, sheds light on the intricate interplay between novel TCR-like antibody therapeutics and human tissue environments, unlocking crucial insights that pave the way for enhanced efficacy and safety in therapeutic interventions.

You can read Estelle’s paper, titled “The physiological interactome of TCR-like antibody therapeutics in human tissues,” here: https://lnkd.in/eSGfSV78

Huge congratulations to Dr. Marrer-Berger and the entire team for this remarkable achievement! This reinforces 3 T’s commitment to using great science to develop immunotherapies that dramatically improve treatments for patients in need.

#BioTech #Immunotherapy #Roche #NatureCommunications

We are pleased to share some important leadership changes to enhance our research and development efforts. Marvin Gee has been promoted to Chief Research Officer, recognizing his leadership in establishing our T cell receptor (TCR)-based therapy research platform. We also welcome Barbara Sennino as Senior Vice President and Head of Early Development, bringing her extensive expertise in cancer immunotherapy and early-stage therapeutic development. These appointments strengthen our scientific and translational expertise as we move closer to clinical trials.

Link to press release: https://lnkd.in/eb9F4WMQ

#Biopharma #Biotechnology #LifeSciences

Boehringer offers 3T Biosciences $268M to plug its data into biotech's TCR cancer platform - Fierce Biotech

Leah Sibener: For Us, Success Is Helping People - Forbes

Novel T cell receptor-based solid tumor therapies - Nature.com

 Co-stimulatory domains for use in genetically-modified cells 

At 3T Biosciences, we have generated significant interest from potential pharmaceutical partners. By leveraging our unique position in the market and our innovative approaches, we are poised to form collaborations that could accelerate our research and development efforts. 

Connect with us to explore potential partnerships in advancing cancer treatment. https://lnkd.in/gCg3mhez

#JPM2025 #JPM25 #BioPharma #Biotech #Immunotherapy #PrecisionOncology

 Boehringer–3T Biosciences: cancer immunotherapies, 202301– strategic collab + license agreem RnD of cancer therapies using 3T-TRACE discovery platform 

We're thrilled to share insights from our CEO, Stefan J. Scherer M.D., Ph.D., who was featured in the latest #BusinessofBiotech podcast episode with Matthew Pillar. Recorded at the J.P. Morgan Healthcare Conference, this conversation highlights our journey from a research-focused platform to a clinical-stage biopharmaceutical company.
 
You can go ahead and swipe below to look through some key discussion points. 
 
You can listen to the full conversation on YouTube at: https://lnkd.in/g2rZ2EJX
 
#Biotech #Innovation #Leadership #CancerResearch #Oncology #ArtficialIntelligence #AI

3T Biosciences

Business:

Drug notes:

About: